<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="research-article"        dtd-version="1.4">
            <front>

                <journal-meta>
                                    <journal-id></journal-id>
            <journal-title-group>
                                                                                    <journal-title>Journal of Uludağ University Medical Faculty</journal-title>
            </journal-title-group>
                            <issn pub-type="ppub">1300-414X</issn>
                                        <issn pub-type="epub">2645-9027</issn>
                                                                                            <publisher>
                    <publisher-name>Bursa Uludağ University</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id/>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>​Internal Diseases</subject>
                                                            <subject>Intensive Care</subject>
                                                            <subject>Clinical Sciences (Other)</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>İç Hastalıkları</subject>
                                                            <subject>Yoğun Bakım</subject>
                                                            <subject>Klinik Tıp Bilimleri (Diğer)</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                        <trans-title-group xml:lang="tr">
                                    <trans-title>Dahiliye Yoğun Bakım Hastalarında Potansiyel İlaç Etkileşimlerinin, Farklı Veri Tabanları Kullanılarak Karşılaştırmalı Olarak İncelenmesi</trans-title>
                                </trans-title-group>
                                                                                                                                                                                                <article-title>Comparative Evaluation of Potential Drug Interactions in Internal Medicine Intensive Care Unit Patients Using Different Databases</article-title>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0001-8839-8444</contrib-id>
                                                                <name>
                                    <surname>Özyürek</surname>
                                    <given-names>Ahmet</given-names>
                                </name>
                                                                    <aff>Turkish Medicines and Medical Devices Agency, Department of Analysis and Control Laboratories, Çankaya/Ankara, Türkiye</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0003-4068-5860</contrib-id>
                                                                <name>
                                    <surname>Aysin</surname>
                                    <given-names>Murat</given-names>
                                </name>
                                                                    <aff>Balıkesir University, Faculty of Medicine, Public Health, Altıeylül/Balıkesir, Türkiye</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0002-4474-9617</contrib-id>
                                                                <name>
                                    <surname>Yılmaz</surname>
                                    <given-names>İsmail</given-names>
                                </name>
                                                                    <aff>Izmir Katip Celebi University, Faculty of Medicine, Medical Pharmacology, Çiğli/İzmir, Türkiye</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0000-0000-0000</contrib-id>
                                                                <name>
                                    <surname>Yıldırım</surname>
                                    <given-names>Ali</given-names>
                                </name>
                                                                    <aff>İzmir Atatürk Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, Karabağlar/İzmir, Türkiye</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20251208">
                    <day>12</day>
                    <month>08</month>
                    <year>2025</year>
                </pub-date>
                                        <volume>51</volume>
                                        <issue>3</issue>
                                        <fpage>419</fpage>
                                        <lpage>426</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20250814">
                        <day>08</day>
                        <month>14</month>
                        <year>2025</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20250926">
                        <day>09</day>
                        <month>26</month>
                        <year>2025</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 1975, Journal of Uludağ University Medical Faculty</copyright-statement>
                    <copyright-year>1975</copyright-year>
                    <copyright-holder>Journal of Uludağ University Medical Faculty</copyright-holder>
                </permissions>
            
                                                                                                <trans-abstract xml:lang="tr">
                            <p>İlaç etkileşimleri, yoğun bakım ünitelerinde sıkça karşılaşılan önemli bir sağlık sorunudur. Çalışmamızın amacı, daha güncel veriler elde etmek ve ilaç etkileşimleri konusunda farkındalığı artırmaktır. 2019 yılında yoğun bakım ünitesine yatışı yapılan 163 hastanın verileri retrospektif olarak analiz edildi. Hastaların ilaç listeleri günlük bazda değerlendirildi ve üç farklı çevrimiçi veri tabanı kullanılarak ilaç bilgileri analiz edildi. Toplam 1.834 ilaç reçetesi incelendi. En sık yatış tanıları pnömoni, akut böbrek yetmezliği ve gastrointestinal kanama idi. Eşlik eden hastalık sayısı ve ilaç sayısı arttıkça etkileşim sayısı anlamlı şekilde arttı. Bu ilişki özellikle kardiyovasküler hastalıklar için belirgindi. Etkileşim sayısı erkeklerde daha yüksekti. Etkileşimler Micromedex’te reçetelerin %82,9’unda, Lexicomp’ta %92,5’inde ve Drugs.com’da %95,5’inde tespit edildi. En sık kontrendike etkileşim linezolid ile tramadol arasında, en sık majör etkileşim ise aspirin ile enoksaparin arasında görüldü. İlaç etkileşimlerinin değerlendirilmesi, hasta sonuçlarının iyileştirilmesine ve gereksiz ekonomik yükün önlenmesine yol açabilir. Klinik hekimler bu değerlendirmeleri yaparken birden fazla kaynaktan yararlanmalıdır. Veri tabanları arasında önemli farklılıklar mevcuttur.</p></trans-abstract>
                                                                                                                                    <abstract><p>Drug interactions are a significant healthcare concern frequently encountered in intensive care units. Our study aims to acquire more up-to-date data and raise awareness of drug interactions. A retrospective analysis was performed on the data of 163 patients admitted to the intensive care unit in 2019. The patients&#039; medication lists were evaluated on a daily basis, and drug information was analyzed using three different online databases, and1,834 medication orders were analyzed. The most common admission diagnoses were pneumonia, acute renal failure, and gastrointestinal bleeding. The number of interactions increased significantly with increasing comorbidities and number of drugs. This association was particularly evident for cardiovascular diseases. The number of interactions was higher in men. Interactions were identified in 82.9% of orders in Micromedex, 92.5% in Lexicomp, and 95.5% in Drugs.com. The most common contraindicated interaction was between linezolid and tramadol, while the most common major interaction was between aspirin and enoxaparin. Assessment of drug interactions can lead to improved patient outcomes and avoidance of unnecessary economic burden. Clinicians should use several sources when performing such assessments. There are significant differences between the databases.</p></abstract>
                                                            
            
                                                                                        <kwd-group>
                                                    <kwd>Drug Interactions</kwd>
                                                    <kwd>  Intensive Care</kwd>
                                                    <kwd>  Polypharmacy</kwd>
                                                    <kwd>  Databases</kwd>
                                            </kwd-group>
                            
                                                <kwd-group xml:lang="tr">
                                                    <kwd>İlaç etkileşimleri</kwd>
                                                    <kwd>  yoğun bakım</kwd>
                                                    <kwd>  polifarmasi</kwd>
                                                    <kwd>  veri tabanları</kwd>
                                            </kwd-group>
                                                                                                                                        </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">1. Borda IT, Slone D, Jick H. Assessment of Adverse Reactions Within a Drug Surveillance Program. JAMA. 1968;205(9):645-647. doi:10.1001/JAMA.1968.03140350055016</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">2. Costa AJ. Potential Drug Interactions in an Ambulatory Geriatric Population. Fam Pract. 1991;8(3):234-236. doi:10.1093/FAMPRA/8.3.234</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">3. Preventable Adverse Drug Reactions: A Focus on Drug Interactions | FDA. Accessed June 12, 2023. https://www.fda.gov/drugs/drug-interactions-labeling/preventable-adverse-drug-reactions-focus-drug-interactions</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">4. Karas S. The potential for drug interactions. Ann Emerg Med. 1981;10(12):627-630. doi:10.1016/S0196-0644(81)80085-6</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">5. Reis AMM, Cassiani SHDB. Adverse drug events in an intensive care unit of a university hospital. Eur J Clin Pharmacol. 2011;67(6):625-632. doi:10.1007/S00228-010-0987-Y</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">6. Ali I, Bazzar A, Hussein N, Sahhar E. Potential drug-drug interactions in ICU patients: a retrospective study. Drug Metab Pers Ther. 2020;35(3). doi:10.1515/DMPT-2020-0114</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">7. Rahimi B. Prevalance of Potential Drug Interactions in Patients in the Intensive Care Unit of Urmia Taleghani Hospital Web-Based Dental PACS in Urmia View Project Breast Feeding Dose-Response Relationship with Breast Cancer View Project.; 2013. https://www.researchgate.net/publication/259306060</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">8. Radder R, M PB. Drug-drug interaction study in an intensive care unit: An assessment of prevalence, nature, and severity of the medications involved. Natl J Physiol Pharm Pharmacol. 2019;290. doi:10.5455/njppp.2019.9.010230402</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">9. Rodrigues AD. Drug-Drug Interactions, Second Edition. Drug-Drug Interactions, Second Edition. Published online January 1, 2019:1-744. doi:10.1201/9780429131967</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">10. Dagdelen MŞ, Gulen D, Ceylan I, Girgin NK. Evaluation of potential drug-drug interactions in intensive care unit. Eur Rev Med Pharmacol Sci. 2021;25(18):5801-5806. doi:10.26355/EURREV_202109_26798</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">11. Garpestad E, Devlin JW. Polypharmacy and Delirium in Critically Ill Older Adults: Recognition and Prevention. Clin Geriatr Med. 2017;33(2):189-203. doi:10.1016/J.CGER.2017.01.002</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">12. Beckett RD, Stump CD, Dyer MA. Evaluation of drug information resources for drug-ethanol and drug-tobacco interactions. J Med Libr Assoc. 2019;107(1):62. doi:10.5195/JMLA.2019.549</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">13. Grannell L. Drug interaction resources: mind the gaps. Aust Prescr. 2020;43(1):18. doi:10.18773/AUSTPRESCR.2020.005</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">14. Shariff A, Sridhar SB, Basha NFA, Alshemeil SSHBT, Noora Adel Ahmed Aljallaf Alzaabi I. Assessing Consistency of Drug-Drug Interaction-Related Information Across Various Drug Information Resources. Cureus. 2021;13(3). doi:10.7759/CUREUS.13766</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">15. Hecker M, Frahm N, Bachmann P, et al. Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases. Front Pharmacol. 2022;13:946351. doi:10.3389/FPHAR.2022.946351/BIBTEX</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">16. Kheshti R, Aalipour M, Namazi S. A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5(4):257. doi:10.4103/2279-042X.192461</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">17. Reis AMM, Cassiani SHDB. Evaluation of three brands of drug interaction software for use in intensive care units. Pharmacy World and Science. Published online December 21, 2010. doi:10.1007/S11096-010-9445-2/TABLES/4</mixed-citation>
                    </ref>
                                    <ref id="ref18">
                        <label>18</label>
                        <mixed-citation publication-type="journal">18. Westreich D. Berksons bias, selection bias, and missing data. Epidemiology. 2012;23(1):159-164. doi:10.1097/EDE.0B013E31823B6296</mixed-citation>
                    </ref>
                                    <ref id="ref19">
                        <label>19</label>
                        <mixed-citation publication-type="journal">19. Patel RI, Beckett RD. Evaluation of resources for analyzing drug interactions. J Med Libr Assoc. 2016;104(4):290. doi:10.3163/1536-5050.104.4.007</mixed-citation>
                    </ref>
                                    <ref id="ref20">
                        <label>20</label>
                        <mixed-citation publication-type="journal">20. Clauson KA, Marsh WA, Polen HH, Seamon MJ, Ortiz BI. Clinical decision support tools: Analysis of online drug information databases. BMC Med Inform Decis Mak. 2007;7(1):1-7. doi:10.1186/1472-6947-7-7/TABLES/5</mixed-citation>
                    </ref>
                                    <ref id="ref21">
                        <label>21</label>
                        <mixed-citation publication-type="journal">21. Marcath LA, Xi J, Hoylman EK, Kidwell KM, Kraft SL, Hertz DL. Comparison of nine tools for screening drug-drug interactions of oral oncolytics. J Oncol Pract. 2018;14(6):e368-e374. doi:10.1200/JOP.18.00086</mixed-citation>
                    </ref>
                                    <ref id="ref22">
                        <label>22</label>
                        <mixed-citation publication-type="journal">22. Shakeel F, Fang F, Kidwell KM, Marcath LA, Hertz DL. Comparison of eight screening tools to detect interactions between herbal supplements and oncology agents. https://doi.org/101177/1078155220905009. 2020;26(8):1843-1849. doi:10.1177/1078155220905009</mixed-citation>
                    </ref>
                                    <ref id="ref23">
                        <label>23</label>
                        <mixed-citation publication-type="journal">23. Chelkeba L, Alemseged F, Bedada W. Assessment of potential drug-drug interactions among outpatients receiving cardiovascular medications at Jimma University specialized hospital, South West Ethiopia. Int J Basic Clin Pharmacol. 2013;2(2):144. doi:10.5455/2319-2003.ijbcp20130306</mixed-citation>
                    </ref>
                                    <ref id="ref24">
                        <label>24</label>
                        <mixed-citation publication-type="journal">24. Straubhaar B, Krähenbühl S, Schlienger RG. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. Drug Saf. 2006;29(1):79-90. doi:10.2165/00002018-200629010-00006/FIGURES/TAB5</mixed-citation>
                    </ref>
                                    <ref id="ref25">
                        <label>25</label>
                        <mixed-citation publication-type="journal">25. Reis AMM, Cassiani SH de B, Max A, et al. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. 2011;66(1):9-15. doi:10.1590/S1807-59322011000100003</mixed-citation>
                    </ref>
                                    <ref id="ref26">
                        <label>26</label>
                        <mixed-citation publication-type="journal">26. Mirosevic Skvrce N, Macolic Sarinic V, Mucalo I, Krnic D, Bozina N, Tomic S. Adverse drug reactions caused by drug-drug interactions reported to Croatian Agency for Medicinal Products and Medical Devices: a retrospective observational study. Croat Med J. 2011;52(5):604. doi:10.3325/CMJ.2011.52.604</mixed-citation>
                    </ref>
                                    <ref id="ref27">
                        <label>27</label>
                        <mixed-citation publication-type="journal">27. Becker CD, Sabang RL, Nogueira Cordeiro MF, Hassan IF, Goldberg MD, Scurlock CS. Hyperglycemia in Medically Critically Ill Patients: Risk Factors and Clinical Outcomes. Am J Med. 2020;133(10):e568-e574. doi:10.1016/J.AMJMED.2020.03.012</mixed-citation>
                    </ref>
                                    <ref id="ref28">
                        <label>28</label>
                        <mixed-citation publication-type="journal">28. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc. 2003;78(12):1471-1478. doi:10.4065/78.12.1471</mixed-citation>
                    </ref>
                                    <ref id="ref29">
                        <label>29</label>
                        <mixed-citation publication-type="journal">29. Bochicchio G V., Sung J, Joshi M, et al. Persistent hyperglycemia is predictive of outcome in critically ill trauma patients. J Trauma. 2005;58(5):921-924. doi:10.1097/01.TA.0000162141.26392.07</mixed-citation>
                    </ref>
                                    <ref id="ref30">
                        <label>30</label>
                        <mixed-citation publication-type="journal">30. Dai D, Feinstein JA, Morrison W, Zuppa AF, Feudtner C. Epidemiology of polypharmacy and potential drug-drug interactions among pediatric patients in ICUs of U.S. children’s hospitals. Pediatric Critical Care Medicine. 2016;17(5):e218-e228. doi:10.1097/PCC.0000000000000684</mixed-citation>
                    </ref>
                                    <ref id="ref31">
                        <label>31</label>
                        <mixed-citation publication-type="journal">31. Kaye AD, Beakley BD, Kaye AM, Kaye AD. Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. Pain Physician. 2015;18:395-400. Accessed August 29, 2023. www.painphysicianjournal.com</mixed-citation>
                    </ref>
                                    <ref id="ref32">
                        <label>32</label>
                        <mixed-citation publication-type="journal">32. Hadjibabaie M, Badri S, Ataei S, Moslehi AH, Karimzadeh I, Ghavamzadeh A. Potential drug-drug interactions at a referral hematology-oncology ward in Iran: A cross-sectional study. Cancer Chemother Pharmacol. 2013;71(6):1619-1627. doi:10.1007/s00280-013-2162-5</mixed-citation>
                    </ref>
                                    <ref id="ref33">
                        <label>33</label>
                        <mixed-citation publication-type="journal">33. DDinter. Accessed September 25, 2023. http://ddinter.scbdd.com/inter-checker/</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
